Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine.

Humans CD8-Positive T-Lymphocytes Antigens, Neoplasm Neoplasms Peptides Epitopes Dendritic Cells
antigen presentation dendritic cell neoantigen neoepitope vaccine

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 16 05 2023
accepted: 26 09 2023
medline: 27 10 2023
pubmed: 26 10 2023
entrez: 26 10 2023
Statut: epublish

Résumé

Neoantigens/ are tumor-specific antigens that evade central immune tolerance mechanisms in the thymus. Long-term tumor-specific cytotoxic T lymphocyte activity maintenance requires class II antigen-reactive CD4

Identifiants

DOI: 10.3389/fimmu.2023.1223331 PMID: 37881436 PMC: PMC10595142
pubmed: 37881436
doi: 10.3389/fimmu.2023.1223331
pmc: PMC10595142
doi:

Substances chimiques

Antigens, Neoplasm 0
Peptides 0
Epitopes 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1223331

Informations de copyright

Copyright © 2023 Morisaki, Onishi, Morisaki, Kubo, Umebayashi, Tanaka, Koya, Nakagawa, Tsujimura, Yoshimura, Yew, Kiyotani, Nakamura, Nakamura, Kitazono and Morisaki.

Déclaration de conflit d'intérêts

Authors PYY and SY are employees of Cancer Precision Medicine Inc. KK is scientific advisor of cancer Precision Medicine, Inc. YN is a stockholder and a scientific advisor of Oncotherapy Science, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nature. 2023 Mar;615(7953):697-704
pubmed: 36890230
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Anticancer Res. 2021 Aug;41(8):4101-4115
pubmed: 34281881
Cancer Sci. 2018 Mar;109(3):542-549
pubmed: 29288513
Trends Cancer. 2018 Feb;4(2):119-137
pubmed: 29458962
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
Front Immunol. 2020 Oct 06;11:592569
pubmed: 33123174
Immunology. 2018 Jul;154(3):394-406
pubmed: 29315598
Nature. 2019 Oct;574(7780):696-701
pubmed: 31645760
Nat Med. 2019 Mar;25(3):389-402
pubmed: 30842677
J Leukoc Biol. 2020 Apr;107(4):625-633
pubmed: 32170883
Cancer Gene Ther. 2021 Feb;28(1-2):5-17
pubmed: 32457487
Oncoimmunology. 2019 Jan 17;8(4):e1560919
pubmed: 30906653
J Immunol. 2007 Oct 15;179(8):5033-40
pubmed: 17911588
Immunity. 2017 Nov 21;47(5):848-861.e5
pubmed: 29126798
Nature. 2014 Nov 27;515(7528):577-81
pubmed: 25428507
Science. 2015 May 15;348(6236):803-8
pubmed: 25837513
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Immunol Invest. 2021 Jul;50(5):562-579
pubmed: 32660279
Eur J Immunol. 2013 Oct;43(10):2554-65
pubmed: 23836147
Cell. 2020 Oct 15;183(2):347-362.e24
pubmed: 33064988
Nat Med. 2004 Sep;10(9):909-15
pubmed: 15340416
J Clin Invest. 2001 Feb;107(4):477-84
pubmed: 11181647
Nature. 2019 Jan;565(7738):234-239
pubmed: 30568305
Immunol Rev. 2016 Jul;272(1):151-68
pubmed: 27319349
Annu Rev Immunol. 2019 Apr 26;37:173-200
pubmed: 30550719
Front Immunol. 2022 Feb 10;13:833017
pubmed: 35222422
Cancers (Basel). 2022 May 15;14(10):
pubmed: 35626042
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6730-5
pubmed: 19346487
J Immunol. 2018 Jan 15;200(2):392-399
pubmed: 29311380
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Clin Cancer Res. 2020 Sep 1;26(17):4511-4520
pubmed: 32439700
Methods Mol Biol. 2018;1802:193-201
pubmed: 29858810
Cancer Sci. 2012 Jan;103(1):150-3
pubmed: 22221328
Theranostics. 2020 May 15;10(13):6011-6023
pubmed: 32483434
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Nat Commun. 2012 Jul 10;3:948
pubmed: 22781761
Front Immunol. 2021 Jun 30;12:696791
pubmed: 34276688
Oncoimmunology. 2017 May 12;6(7):e1328341
pubmed: 28811970
J Exp Med. 1997 Jul 7;186(1):65-70
pubmed: 9206998
Nat Rev Cancer. 2017 Aug 24;17(9):569
pubmed: 28835723
Int J Mol Med. 2015 Jan;35(1):17-23
pubmed: 25395173
J Hum Genet. 2021 Sep;66(9):901-907
pubmed: 34193979
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
Bioinformatics. 2014 Dec 1;30(23):3310-6
pubmed: 25143287
N Engl J Med. 2008 Jun 19;358(25):2698-703
pubmed: 18565862

Auteurs

Shinji Morisaki (S)

Fukuoka General Cancer Clinic, Fukuoka, Japan.
Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Hideya Onishi (H)

Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Takafumi Morisaki (T)

Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Makoto Kubo (M)

Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Masayo Umebayashi (M)

Fukuoka General Cancer Clinic, Fukuoka, Japan.

Hiroto Tanaka (H)

Fukuoka General Cancer Clinic, Fukuoka, Japan.

Norihiro Koya (N)

Fukuoka General Cancer Clinic, Fukuoka, Japan.

Shinichiro Nakagawa (S)

Fukuoka General Cancer Clinic, Fukuoka, Japan.

Kenta Tsujimura (K)

Fukuoka General Cancer Clinic, Fukuoka, Japan.

Sachiko Yoshimura (S)

Corporate Headquarters, Cancer Precision Medicine Inc., Kawasaki, Japan.

Poh Yin Yew (PY)

Corporate Headquarters, Cancer Precision Medicine Inc., Kawasaki, Japan.

Kazuma Kiyotani (K)

National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, Japan.

Yusuke Nakamura (Y)

National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, Japan.

Masafumi Nakamura (M)

Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Takanari Kitazono (T)

Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Takashi Morisaki (T)

Fukuoka General Cancer Clinic, Fukuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Immunological analysis of hybrid neoantigen...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Immunological analysis of hybrid neoantigen...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes néoplasiques › Immunological analysis of hybrid neoantigen...
questionsmedicales.fr › Tumeurs › Immunological analysis of hybrid neoantigen...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Immunological analysis of hybrid neoantigen...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Épitopes › Immunological analysis of hybrid neoantigen...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Système phagocytaire mononucléé › Cellules dendritiques › Immunological analysis of hybrid neoantigen...